Major outcomes during NIH chronic GVHD compared with late acute GVHD
| Outcome without risk factors . | Unadjusted hazard ratio (95% CI) . | Adjusted hazard ratio (95% CI)* . |
|---|---|---|
| Nonrelapse mortality | 1.23 (0.9-1.7) | 1.02 (0.7-1.5) |
| Recurrent malignancy | 0.74 (0.5-1.0) | 0.94 (0.6-1.4) |
| Overall mortality | 1.01 (0.8-1.3) | 0.90 (0.7-1.2) |
| Discontinued systemic treatment | 0.60 (0.5-0.8) | 0.76 (0.6-1.0) |
| Outcome without risk factors . | Unadjusted hazard ratio (95% CI) . | Adjusted hazard ratio (95% CI)* . |
|---|---|---|
| Nonrelapse mortality | 1.23 (0.9-1.7) | 1.02 (0.7-1.5) |
| Recurrent malignancy | 0.74 (0.5-1.0) | 0.94 (0.6-1.4) |
| Overall mortality | 1.01 (0.8-1.3) | 0.90 (0.7-1.2) |
| Discontinued systemic treatment | 0.60 (0.5-0.8) | 0.76 (0.6-1.0) |
In these models, transition from late acute GVHD at onset to NIH chronic GVHD was considered as a competing risk.
Covariates used for adjustment are listed in Table 3.